TORONTO, ON--(Marketwired - November 26, 2013) - Axxess Pharma Inc. (PINKSHEETS: AXXE) a specialty pharmaceutical and nutritional supplements company is pleased to announce, it will establish a Latin American division headquartered in Mexico City, Mexico to handle the Sales & Marketing efforts for the region. Latin America is widely known for their strong interest in the UFC and the TapouT product line. Axxess Pharma anticipates strong revenue within region.
Daniel Bagi, M.D. President of Axxess stated, "The tremendous popularity of the UFC and TapouT in Latin America, especially in Brazil and Mexico necessitates our presence on the ground to manage both our TapouT and pharmaceutical lines. We have already begun the process of establishing Axxess Pharma as a corporate entity in Mexico, and expect to begin operations in the New Year, with sales in the region beginning shortly after." Dr. Bagi, M.D. further stated, "Latin America as a region has a population of over 500 million and is one of the fastest growing markets in the world. With the popularity and growth of the UFC and the TapouT brand, we felt the timing was right for this expansion. We are also very close to submitting pharmaceutical cancer drug dossiers for approval in Mexico. In August of 2013, our Company acquired the Mexican and Latin American rights to the cancer drugs from a leading Canadian manufacturer."
About Axxess Pharma Inc.:
Axxess Pharma Inc. is a Nevada Corporation operating through its wholly-owned Canadian Subsidiary: Axxess Pharma Canada Inc., headquartered in Toronto. Axxess is a specialty Health Care Products Company dedicated to improving health and quality of life by offering select medicines, nutritional supplements and over the counter remedies all across the Americas. Axxess's goal is to bring additional products to the market and provide new, innovative options for better health spanning areas such as high cholesterol, blood pressure, acute pain, - to optimal health management through improved nutritional supplements.
For more information, please visit www.axxesspharmainc.com, or contact Investor Relations at (973) 351-3868.
Safe Harbor Statement
Statements about the Company's future expectations and all other statements in this press release other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby.
The above information contains information relating to the Company that is based on the beliefs of the Company and/or its management, as well as assumptions made by any information currently available to the Company or its management. When used in this document, the words "anticipate," "estimate," "expect," "intend," "plans," "projects," and similar expressions, as they relate to the Company or its management, are intended to identify forward-looking statements. Such statements reflect the current view of the Company regarding future events and are subject to certain risks, uncertainties and assumptions, including the risks and uncertainties noted. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove to be incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated, expected, intended or projected. In each instance, forward-looking information should be considered in light of the accompanying meaningful cautionary statements herein. Factors that could cause results to differ include, but are not limited to, successful performance of internal plans, the impact of competitive services and pricing and general economic risks and uncertainties.